购物车 
-
杆菌肽
NMR and HPLC COA下载 MSDS下载 - Names：
Bacitracin
- CAS号：
1405-87-4
MDL Number： - MF(分子式)： C66H103N17O16S MW(分子量)： 1422.69
- EINECS:215-786-2 Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
杆菌肽(1405-87-4,Bacitracin)是枯草芽孢杆菌var Tracy的地衣形生物产生的相关环状多肽的混合物，其通过干扰细胞壁和肽聚糖合成物而破坏革兰氏阳性和革兰氏阴性细菌。杆菌肽是一种用于葡萄球菌感染的多肽抗生素。杆菌肽通过与焦磷酸十一癸烯基结合，起到抑制细胞壁生物合成的作用。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| SS0344-5g | 5g | 效价>60Units | ¥ 0.00 | ¥ 0.00 | Instock1-2days | ¥ 0.00 | ||
| SS0344-1g | 1g | 效价>60Units | ¥ 1280.00 | ¥ 1280.00 | Instock1-2days | ¥ 0.00 | ||
| SS0344-250mg | 250mg | 效价>60Units | ¥ 460.00 | ¥ 460.00 | Instock1-2days | ¥ 0.00 |
| 中文别名 | 杆菌肽,杆菌肽(1405-87-4,Bacitracin);枯草菌肽;枯草杆菌肽;杆菌肽(标准品);肝菌肽 |
| 英文别名 | Bacitracin(1405-87-4);Altracin; Ayfivin; Baciguent; Fortracin; Parentraci |
| CAS号 | 1405-87-4 |
| Inchi | InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1 |
| InchiKey | CLKOFPXJLQSYAH-ABRJDSQDSA-N |
| 分子式 Molecular Weight | C66H103N17O16S |
| 分子量 Formula | 1422.69 |
| 溶解度Solubility | H2O : 6.67 mg/mL (4.69 mM; Need ultrasonic) |
| 性状 | 白色至浅黄色粉末 |
| 储藏条件 Storage conditions | 4°C，避光 |
杆菌肽(1405-87-4,Bacitracin)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净后，烘干消毒存放。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
Bacitracin(1405-87-4) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:杆菌肽(1405-87-4,Bacitracin),杆菌肽得效价,杆菌肽的作用,杆菌肽的储存条件,杆菌肽的外观,杆菌肽的厂家,杆菌肽的价格,杆菌肽的活性,杆菌肽的使用,杆菌肽的分子量,杆菌肽的MSDS,杆菌肽的注意事项,杆菌肽的制备
| 产品说明 | 杆菌肽(1405-87-4)是一种用于葡萄球菌感染的多肽抗生素,杆菌肽的作用,杆菌肽的其他参数见主页 |
| Introduction | Bacitracin (1405-87-4,杆菌肽) is a polypeptide antibiotic used for staphylococcal infections. The role of 1405-87-4 and other parameters of 1405-87-4 are shown on the homepage |
| Application1 | 杆菌肽通过与焦磷酸十一癸烯基结合，起到抑制细胞壁生物合成的作用。 |
| Application2 | 杆菌肽是由地衣型芽孢杆菌产生的多肽类抗生素 |
| Application3 | 杆菌肽用于研究在肽聚糖的生物合成和异戊二烯的代谢水平打乱细菌细胞壁的合成 |
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | No data available |
| 安全声明 | H303吞入可能有害+H313皮肤接触可能有害+H333吸入可能对身体有害 |
| 安全防护 | P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P313获得医疗建议/护理 |
| 备注 | 实验过程中防止吸入、食入，做好安全防护 |
| Detection of residual bacitracin A, colistin A, and colistin B in milk and animal tissues by liquid chromatography tandem mass spectrometry |
| Characterization of the Mechanism of the Staphylococcus aureus Cell Envelope by Bacitracin and Bacitracin-Metal Ions. |
| Distribution and Variation of Bacitracin Synthetase Gene Sequences in Laboratory Stock Strains of Bacillus licheniformis |
| J.B. Ward Biochem. J. 141, 227, (1974) 2. A. Anastasi et al. Biochem. J. 290, 601, (1993) 3. D.J. Daly et al. Biochem. Soc. Trans. 13, 1161, (1985) |
| E.D. Weinberg, D. Gottlieb and P.D. Shaw, eds. Antibiotics Berlin , 90, (1967) |
1. Detection of residual bacitracin A, colistin A, and colistin B in milk and animal tissues by liquid chromatography tandem mass spectrometry
Eric Chun-hong Wan, Clare Ho, Della Wai-mei Sin , Yiu-chung Wong. Anal Bioanal Chem (2006) 385: 181–188
Bacitracin and colistin are polypeptide antibacterial agents that are used as feedstuff additives to prevent and treat infections and to promote growth in modern animal husbandry. Both compounds consist mainly of amino acids and several different components, depending on the type and combination of amino acids. Bacitracin A (Fig. 1a) is the major component of bacitracin and has potent therapeutic activity towards Grams-positive cocci and bacilli. Colistin was often used for treating diseases caused by Gram-negative bacteria in the 1960s but it was then found to exhibit high toxicity and hence had limited applications in human. Some recent medical studies, on the other hand, reported that colistin was effective against multi-resistant Gram-negative bacteria, in particular Pseudomonas aeruginosa and was proven to be a potential antibiotic for treating multi-resistant strains in clinical settings. Colistin A and colistin B (Fig. 1b) are the major components among the 30 elucidated congeners; they account for more than 85% of the total colistins used in pharmaceutical products. Like other antibiotics, residual bacitracin and colistin in milk and edible animal tissues might lead to the allergies and emergence of resistant microbes. As a consequence, national health authorities have established legal guidance to ensure proper use of bactracin and colistin and other controlled veterinary antibiotics.
2. Characterization of the Mechanism of the Staphylococcus aureus Cell Envelope by Bacitracin and Bacitracin-Metal Ions
Zu-De Qi, Yi Lin, Bo Zhou, Xiao-Di Ren, Dai-Wen Pang, Yi Liu. J Membrane Biol (2008) 225:27–37
Bacitracin, a metal-dependent dodecapeptide produced by Bacillus subtilis and Bacillus licheniformis (Toscano and Storm 1982), was ?rst discovered in 1943 from a bacterial culture isolated from a wound of a 7-year-old American girl (Ming and Epperson 2002). Commercial bacitracin preparations are comprised of a mixture of many closely related analogues, named bacitracin A–I, of which bacitracin A represents the major component with the highest activity (Konigsberg and Craig 1962; Hirotsu et al. 1978). It is also known that bacitracins A and B account for 95% of the biological activity of the mixtures (Tsuji and Robertson 1975). Bacitracin A, a dodecapeptide, contains a heptapeptide cyclic structure and a thiazoline ring formed between the L-cysteine and L-isoleucine located at the N-terminal end of the acylic peptide side chain (Konz et al. 1997). Bacitracin has activity primarily against grampositive cocci and bacilli, including Staphylococcus, Streptococcus and Clostridium dif?cile, as well as some archaea such as Methanobacterium, Mathanococcus and Halococcus (Storm 1974). It has a medical application in the treatment of gastrointestinal infections, such as antibiotic-associated colitis and diarrhea caused by C.dif?cile (Chang et al. 1980). It is widely utilized as an animal feed supplement to improve animal body weight and to prevent diseases in agriculture (Nagaraja and Chengappa 1998; Abdulrahim et al. 1999). Consequently, bacitracin is important to the pharmaceutical and livestock industries throughout the world.
3. Distribution and Variation of Bacitracin Synthetase Gene Sequences in Laboratory Stock Strains of Bacillus licheniformis
Hiroaki Ishihara, Makoto Takoh, Rika Nishibayashi, Atsushi Sato. CURRENT MICROBIOLOGY Vol. 45 (2002), pp. 18–23
Bacillus licheniformis strains produce various peptide antibiotics, e.g., bacitracins, licheniformin, lichenysins, and amoebicins. Bacitracin consists of a group of closely related peptides and bacitracin A is a main component of the peptides. Bacitracins are produced by certain strains of B. licheniformis and B. subtilis, and are synthesized by a multifunctional enzyme system composed of bacitracin synthetases 1, 2, and 3 which are encoded by bacitracin synthetase genes bacA, bacB, and bacC, respectively. Almost all biochemical and molecular biological studies on bacitracin production in B. licheniformis have been carried out with strain ATCC 10716. Cloning and DNA sequencing of the entire bacitracin synthetase gene cluster from this strain have been carried out. We found no reports on distribution of bacitracin synthetase gene sequences among strains of B. licheniformis. Therefore, as the ?rst step in studies on strain speci?city of peptide antibiotic production in Bacillus strains, we investigated distribution of bacitracin syn- thetase gene sequences in laboratory stock strains of B. licheniformis by genomic Southern blot hybridization.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
细胞培养耗材技术领先性
细胞培养板行业面临的核心痛点是：常规TC处理后表面亲水角随时间衰减，影响长期培养稳定性，BIOFOUNT高分...
2026/4/28 15:12:51
细胞培养耗材关键性能
细胞培养板的水接触角作为表面润湿性的核心指标，直接影响细胞贴壁、增殖、分化及功能表达，其中40°（低接触角/...
2026/4/28 14:52:44
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
